http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#Head http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#assertion http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#provenance http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#pubinfo http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#assertion http://purl.obolibrary.org/obo/DOID_289 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_289 http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00014 http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association http://www.w3.org/2000/01/rdf-schema#label zoladex is a gonadotropin releasing hormone gnrh agonist indicated for 1 1 1 2 1 3 1 4 1 5 zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b t4 stage b2 c carcinoma of the prostate treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy see dosage and administration 2 1 and clinical studies 14 1 zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate see dosage and administration 2 2 clinical studies 14 2 zoladex is indicated for the management of endometriosis including pain relief and reduction of endometriotic lesions for the duration of therapy experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months see dosage and administration 2 3 clinical studies 14 3 zoladex is indicated for use as an endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding see dosage and administration 2 4 clinical studies 14 4 zoladex is indicated for use in the palliative treatment of advanced breast cancer in pre and perimenopausal women the estrogen and progesterone receptor values may help to predict whether zoladex therapy is likely to be beneficial see dosage and administration 2 6 clinical pharmacology 12 1 clinical studies 14 5 the automatic safety feature of the syringe aids in the prevention of needlestick injury http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00014 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#provenance http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#pubinfo http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#sig http://purl.org/nanopub/x/hasSignature CgDM5Ozx+3KBVVChJ7qUFFYRGdJV7YTmWh3P6tqeTvVffxEp3+ZptZiXvnrHs6+p7hal3FI+LxJe7jGRUARpOetDcbTa5kfU9+b+VZvxIloofaUqasp6hUJ6159l3IaRAjfNQQYuObNIWfwtCaQCcKp+TyjZsocBw86Aub0gyso= http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI http://purl.org/dc/terms/created 2021-06-30T09:02:23.100+02:00 http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs